Please login to the form below

Not currently logged in
Email:
Password:

COVID-19 and coronavirus

Russia says its Sputnik V COVID-19 vaccine is 91.4% effective

Russia says its Sputnik V COVID-19 vaccine is 91.4% effective

Preliminary data demonstrates efficacy of 95% after 42 days. Russia has announced new data for its COVID-19 vaccine Sputnik V, saying in a statement that the vaccine is 91.4% ... The initial analysis from the first 16, 000 participants to receive both

Latest news

More from news
Approximately 0 fully matching, plus 214 partially matching documents found.

Latest Intelligence

  • How will COVID-19 affect uptake of vaccinations against other diseases? How will COVID-19 affect uptake of vaccinations against other diseases?

    Will COVID-19 help or hinder the quest to increase uptake of other vaccinations? ... Not just for the COVID-19 programmes, but for every other vaccine made these days.

  • The impact of COVID-19 on clinical trials The impact of COVID-19 on clinical trials

    The novel coronavirus (COVID-19) pandemic has created an unprecedented global health crisis and all industry sectors are working to assess both the impact and the optimal path forward. ... Clinical trials with the following characteristics are especially

  • COVID-19 hits supply chains COVID-19 hits supply chains

    Too much, way too much, cried our leaders, as the coronavirus (COVID-19) pandemic shuttered factories in the Hubei province. ... Reaction to the coronavirus crisis sheds light on fundamental shifts occurring in the US political landscape, according to

  • Developing a COVID-19 vaccine Developing a COVID-19 vaccine

    GlaxoSmithKline has also partnered with Chinese biotech company Clover Biopharmaceuticals on a protein-based coronavirus vaccine candidate, named COVID-19 S-Trimer. ... French drugmaker Sanofi also currently has two ongoing collaborations to develop a

  • As COVID-19 takes over the world, biopharma fights back As COVID-19 takes over the world, biopharma fights back

    The novel coronavirus, which causes the respiratory disease COVID-19, has overwhelmed healthcare systems and led to strict lockdowns in countries across the world as governments fight to tackle the spread ... French immunologist Didier Raoult has

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

  • White paper for download: Maintaining market access continuity through a global pandemic White paper for download: Maintaining market access continuity through a global pandemic

    In a Valid Insight webinar, we brought together key stakeholders to discuss the global coronavirus (COVID-19) pandemic and its effects on pharmaceutical pricing and market access. ... Preparing for a post-COVID-19 future in market access, including how

  • Speakers Announced: Maintaining Market Access Continuity through a Global Pandemic Webinar Speakers Announced: Maintaining Market Access Continuity through a Global Pandemic Webinar

    The global outbreak of coronavirus (COVID-19) and subsequent perception of public health risk creates challenges for international business continuity and market access planning.

  • Will COVID-19 necessitate a change in thinking around clinical trials? Will COVID-19 necessitate a change in thinking around clinical trials?

    The global outbreak of coronavirus (COVID-19) and current misinformation infiltrating our consciousness on social media has been a challenge to get our heads around, but it’s undeniable that ... This blog was first published here:

  • Could coronavirus turn us all into online gamers? Could coronavirus turn us all into online gamers?

    As businesses gauge the potential impact of coronavirus (COVID-19), with a sense of fear and pessimism causing a dampening of economic activity and suspension of the stock market, the healthcare ... We’ve put our actively considerate heads together and

  • Keeping calm and carrying on: COVID-19 and approaches to CME/CPD during a viral outbreak

    Celeste Kolanko, Managing Director, Liberum OPEN Health. As the incidences of the Coronavirus COVID-19 are growing, it’s a good time to reflect on its effects on CME/CPD to

  • Page & Page and Partners Page & Page and Partners

    COVID-19 resulted in the rapid adoption of virtual consultations; while they offer increased accessibility and convenience for some, are they really all they are cracked up to be? ... As businesses gauge the potential impact of coronavirus (COVID-19),

  • Valid Insight Valid Insight

    The global outbreak of coronavirus (COVID-19) and subsequent perception of public health risk creates challenges for international business continuity and market access planning. ... In a Valid Insight webinar, we brought together key stakeholders to

  • COUCH Health COUCH Health

    Traditional clinical trial designs simply can’t withstand the impact of COVID-19. ... The global outbreak of coronavirus (COVID-19) and current misinformation infiltrating our consciousness on social media has been a challenge to get our heads around,

More from PMHub
Approximately 0 fully matching, plus 8 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...
Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...

Infographics